Mayo Clinic Ophthalmology Podcast: The ophthalmologist on the face transplant team

• June 11, 2024

Error in Figure

• September 14, 2026

FDA clears targeted cholangiocarcinoma therapy

In the single-arm REFOCUS trial, 46% of patients responded to treatment, with a median response duration of 11.8 months.

• by Kathryn Wighton

• September 24, 2026

• 2 min

Glycemic variability may signal retinal changes

Greater glucose fluctuations but not HbA1c were associated with neuroretinal alterations over 3 years in pediatric patients with type 1 diabetes.

• by Andrea Surnit

• September 1, 2026

• 3 min